Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Clin Exp Dermatol ; 46(7): 1299-1303, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33760256

RESUMEN

Toxic epidermal necrosis (TEN)-like lupus is a rare condition characterized by epidermal loss and mucosal ulceration occurring in patients with acute severe flares of systemic lupus erythematosus. The clinical picture may mimic drug-induced Stevens-Johnson syndrome/TEN; however, the absence of a suitable culprit drug, and the context of acute lupus point to the correct diagnosis. In a case series of three patients, further discriminating features included a slower onset of epidermal loss, more limited mucosal ulceration and a lack of ocular involvement when compared with drug-induced TEN. Histology may show similar features, including basal layer vacuolation, apoptosis and full-thickness epidermal necrosis. Patients with TEN-like lupus may have additional features of lupus, and a lupus band on direct immunofluorescence. It is important to identify this condition correctly, so that these patients can be appropriately managed with early input from Rheumatologists and prompt treatment with high-dose combined immunosuppressant therapy.


Asunto(s)
Lupus Eritematoso Sistémico/diagnóstico , Piel/patología , Síndrome de Stevens-Johnson/diagnóstico , Adulto , Anciano , Diagnóstico Diferencial , Femenino , Humanos , Lupus Eritematoso Sistémico/patología , Persona de Mediana Edad , Síndrome de Stevens-Johnson/patología
3.
Cell Death Dis ; 5: e1528, 2014 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-25412306

RESUMEN

Cellular senescence is a terminal differentiation state that has been proposed to have a role in both tumour suppression and ageing. This view is supported by the fact that accumulation of senescent cells can be observed in response to oncogenic stress as well as a result of normal organismal ageing. Thus, identifying senescent cells in in vivo and in vitro has an important diagnostic and therapeutic potential. The molecular pathways involved in triggering and/or maintaining the senescent phenotype are not fully understood. As a consequence, the markers currently utilized to detect senescent cells are limited and lack specificity. In order to address this issue, we screened for plasma membrane-associated proteins that are preferentially expressed in senescent cells. We identified 107 proteins that could be potential markers of senescence and validated 10 of them (DEP1, NTAL, EBP50, STX4, VAMP3, ARMX3, B2MG, LANCL1, VPS26A and PLD3). We demonstrated that a combination of these proteins can be used to specifically recognize senescent cells in culture and in tissue samples and we developed a straightforward fluorescence-activated cell sorting-based detection approach using two of them (DEP1 and B2MG). Of note, we found that expression of several of these markers correlated with increased survival in different tumours, especially in breast cancer. Thus, our results could facilitate the study of senescence, define potential new effectors and modulators of this cellular mechanism and provide potential diagnostic and prognostic tools to be used clinically.


Asunto(s)
Envejecimiento/genética , Biomarcadores de Tumor/genética , Neoplasias de la Mama/genética , Proteínas de la Membrana/genética , Proteínas Tirosina Fosfatasas Clase 3 Similares a Receptores/genética , Microglobulina beta-2/genética , Envejecimiento/metabolismo , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Línea Celular Tumoral , Senescencia Celular/genética , Femenino , Humanos , Proteínas de la Membrana/metabolismo , Proteínas Tirosina Fosfatasas Clase 3 Similares a Receptores/metabolismo , Análisis de Supervivencia , Microglobulina beta-2/metabolismo
5.
Pharmazie ; 66(8): 623-7, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21901988

RESUMEN

We examined the sedative, anxiolytic and antidepressant effects of essential oil (EO) of leaves from Citrus limon, which has been used as one of the most popular compounds in Brazilian traditional herbal medicine. The effects of EO were demonstrated by open-field, elevated-plus-maze, rota rod, pentobarbital-induced sleeping time, and forced swimming tests in mice. In the open-field test, EO at the doses of 50, 100 and 150 mg/kg, after oral administration, significantly decreased the number of crossings, grooming, and rearing. In the elevated-plus-maze (EPM) test, EO increased the time of permanence and the number of entrances in the open arms. On the contrary, the time of permanence and the number of entrances in the closed arms were decreased. In the rota rod test, EO did not alter motor coordination and, thus, was devoid of effects, as related to controls. In the pentobarbital-induced sleeping time test, EO at the same doses significantly increased the animals sleeping time duration. Since EO, at the doses of 50, 100 and 150 mg/kg, did not show a sedative effect in the open field test, these three doses were used in the forced swimming test, producing a decrease in the immobility time, similarly to that of imipramine (positive control). However, the antidepressant effects of EO were not altered by the previous administration of paroxetine. In addition, effects of EO in the forced swimming test were totally blocked by reserpine pretreatment. In conclusion, the present work evidenced sedative and anxiolytic effects of EO that might involve an action on benzodiazepine-type receptors, and also an antidepressant effect where noradrenergic and serotoninergic mechanisms will probably play a role.


Asunto(s)
Ansiolíticos , Antidepresivos , Citrus/química , Hipnóticos y Sedantes , Aceites Volátiles/farmacología , Animales , Conducta Animal/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Cromatografía de Gases y Espectrometría de Masas , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Pentobarbital/farmacología , Equilibrio Postural/efectos de los fármacos , Sueño/efectos de los fármacos , Natación/psicología
7.
Arq. neuropsiquiatr ; 69(2b): 360-364, 2011. ilus, tab
Artículo en Inglés | LILACS | ID: lil-588098

RESUMEN

Pilocarpine-induced seizures can be mediated by increases in oxidative stress and by cerebral amino acid changes. The present research suggests that antioxidant compounds may afford some level of neuroprotection against the neurotoxicity of seizures in cellular level. The objective of the present study was to evaluate the lipoic acid (LA) effects in glutamate and taurine contents in rat hippocampus after pilocarpine-induced seizures. Wistar rats were treated intraperitoneally (i.p.) with 0.9 percent saline (Control), pilocarpine (400 mg/kg, Pilocarpine), LA (10 mg/kg, LA), and the association of LA (10 mg/kg) plus pilocarpine (400 mg/kg), that was injected 30 min before of administration of LA (LA plus pilocarpine). Animals were observed during 24 h. The amino acid concentrations were measured using high-performance liquid chromatograph (HPLC). In pilocarpine group, it was observed a significant increase in glutamate content (37 percent) and a decrease in taurine level (18 percent) in rat hippocampus, when compared to control group. Antioxidant pretreatment significantly reduced the glutamate level (28 percent) and augmented taurine content (32 percent) in rat hippocampus, when compared to pilocarpine group. Our findings strongly support amino acid changes in hippocampus during seizures induced by pilocarpine, and suggest that glutamate-induced brain damage plays a crucial role in pathogenic consequences of seizures, and imply that strong protective effect could be achieved using lipoic acid through the release or decrease in metabolization rate of taurine amino acid during seizures.


As convulsões induzidas pela pilocarpina podem ser mediadas através do aumento do estresse oxidativo cerebral e das alterações na concentração dos aminoácidos. O presente estudo sugere que compostos antioxidantes podem produzir neuroproteção contra a neurotoxicidade em nível celular causada pelas convulsões. O objetivo deste estudo foi avaliar os efeitos do ácido lipóico (AL) no conteúdo de glutamato e taurina no hipocampo de ratos durante convulsões induzidas por pilocarpina. Ratos Wistar foram tratados por via intraperitoneal com solução salina 0,9 por cento (controle), pilocarpina (400 mg/kg, pilocarpina), AL (10 mg/kg) e com a associação de AL (10 mg/kg); 30 min após com pilocarpina (400 mg/kg), que foi injetada 30 min após a administração de AL (AL + pilocarpina). Os animais foram observados durante 24 horas. As concentrações de aminoácidos foram determinadas por HPLC. No hipocampo dos ratos do grupo pilocarpina foi observado um aumento significativo de 37 por cento na concentração de glutamato e uma diminuição de 18 por cento no nível de taurina, quando comparado ao grupo controle. O pré-tratamento com o antioxidante reduziu significativamente o nível de glutamato em 28 por cento e aumentou em 32 por cento os níveis de taurina no hipocampo dos ratos, quando comparado ao grupo pilocarpina. Nossos resultados sugerem que ocorrem alterações na concentração dos aminoácidos no hipocampo de ratos durante as convulsões induzidas por pilocarpina, e que o glutamato pode desempenhar um papel crucial na fisiopatologia das convulsões, e que o efeito protetor poderia ser alcançado com pré-tratamento com ácido lipóico, provavelmente pelo aumento da liberação ou redução da taxa de metabolização dos aminoácidos durante as convulsões.


Asunto(s)
Animales , Masculino , Ratas , Antioxidantes/farmacología , Ácido Glutámico/metabolismo , Hipocampo/efectos de los fármacos , Convulsiones/metabolismo , Taurina/metabolismo , Ácido Tióctico/farmacología , Cromatografía Líquida de Alta Presión , Hipocampo/química , Pilocarpina , Ratas Wistar , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico
8.
Neurosci Lett ; 469(1): 81-3, 2010 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-19932735

RESUMEN

In the present study we investigated the alterations on choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities in rat striatum and frontal cortex caused by pilocarpine-induced seizures. Wistar rats were treated with 0.9% saline (i.p., control group), with the association of 0.9% saline (i.p.) plus pilocarpine (400mg/kg, i.p.), 30 min before of administration of saline (pilocarpine group). After the treatments all groups were observed for 1h. The ChAT and AChE activities were measured using spectrophotometric methods and the results compared to values obtained from saline-treated animals. In pilocarpine group was observed a significantly decreases in ChAT and AChE activities in striatum and frontal cortex of adult rats, when compared to control group. Results showed that during acute phase of seizures striatal and frontal cortex ChAT and AChE activities are diminished. Our findings suggest that seizures caused cognitive dysfunction and decreases of ChAT and AChE activities that might be related, at least in part, to the neurological problems presented by epileptic patients.


Asunto(s)
Acetilcolinesterasa/metabolismo , Colina O-Acetiltransferasa/metabolismo , Cuerpo Estriado/enzimología , Lóbulo Frontal/enzimología , Pilocarpina , Convulsiones/enzimología , Animales , Masculino , Ratas , Ratas Wistar , Convulsiones/inducido químicamente
9.
Br J Dermatol ; 161(2): 364-72, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19438459

RESUMEN

BACKGROUND: The relationships between so-called spitzoid tumours have proven difficult to understand. OBJECTIVES: To address three questions: does spitzoid tumour morphological similarity reflect molecular similarity? Does Spitz naevus progress into spitzoid melanoma? Are ambiguous spitzoid tumours genuine entities? METHODS: BRAF, NRAS and HRAS mutations were analysed using single-strand conformational polymorphism analysis and sequencing. RESULTS: Both Spitz naevi and spitzoid melanoma had a lower combined BRAF and NRAS mutation frequency compared with common acquired naevi (P = 0.0001) and common forms of melanoma (P = 0.0072), respectively. To look for evidence of progression from Spitz naevi to spitzoid melanoma, HRAS was analysed in 21 spitzoid melanomas, with no mutations identified. The binomial probability of this was 0.03 based on an assumption of a 15% mutation frequency in Spitz naevi with unbiased progression. Under these assumptions, HRAS mutations must be rare/absent in spitzoid melanoma. Thus, Spitz naevi seem unlikely to progress into spitzoid melanoma, implying that ambiguous spitzoid tumours cannot be intermediate degrees of progression. In addition, the data suggest that HRAS mutation is a potential marker of benign behaviour, in support of which none of three HRAS mutant spitzoid cases metastasized. CONCLUSIONS: First, the morphological similarity of spitzoid tumours reflects an underlying molecular similarity, namely a relative lack of dependence on BRAF/NRAS mutations. Second, Spitz naevi do not appear to progress into spitzoid melanoma, and consequently ambiguous spitzoid tumours are likely to be unclassifiable Spitz naevi or spitzoid melanoma rather than genuine entities. Third, HRAS mutation may be a marker of Spitz naevus, raising the possibility that other molecular markers for discriminating Spitz naevi from spitzoid melanoma can be discovered.


Asunto(s)
Melanoma/genética , Mutación/genética , Nevo de Células Epitelioides y Fusiformes/genética , Proteínas Proto-Oncogénicas B-raf/genética , Proteínas Proto-Oncogénicas p21(ras)/genética , Neoplasias Cutáneas/genética , Adulto , Análisis Mutacional de ADN , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Humanos , Masculino , Melanoma/patología , Nevo de Células Epitelioides y Fusiformes/patología , Polimorfismo Conformacional Retorcido-Simple , Neoplasias Cutáneas/patología
10.
Br J Dermatol ; 158(1): 4-14, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17916202

RESUMEN

Spitzoid tumours are a morphologically diverse group of lesions that share histological similarity to the Spitz naevus, a benign melanocytic skin tumour. Distinguishing classic Spitz naevi from cutaneous malignant melanoma is usually achievable on standard histology sections, but occasionally equivocal lesions are encountered that show features intermediate between these two entities and consequently generate considerable clinical and histopathological concern. The nomenclature and diagnostic criteria for spitzoid lesions are not standardized and this article begins by considering the adverse effect this has on our understanding of spitzoid tumour biology. Investigations of some of the hallmark features of cancer and neoplasia in spitzoid tumours are described, and the contribution of these studies to our understanding of spitzoid tumour biology is considered, along with their potential diagnostic utility. These studies compare spitzoid tumours with better-characterized melanocytic lesions, and from such comparisons assumptions concerning the biological nature of different spitzoid tumours can be made. In contrast, investigations of the mitogen-activated protein kinase (MAPK) pathway and DNA gains and losses have suggested that Spitz naevi may be genetically distinct from other melanocytic tumours. The studies that led to this conclusion are reviewed, as well as subsequent work examining whether the same applies to all spitzoid tumours. Possible explanations for the considerable inconsistencies within some of these data are explored. Finally, potential pathways of tumour progression within spitzoid lesions are considered, with an emphasis placed upon insights gained from investigations of MAPK genes and DNA gains and losses.


Asunto(s)
Nevo de Células Epitelioides y Fusiformes/genética , Neoplasias Cutáneas/genética , Diagnóstico Diferencial , Progresión de la Enfermedad , Humanos , Sistema de Señalización de MAP Quinasas/genética , Melanoma/diagnóstico , Melanoma/genética , Nevo de Células Epitelioides y Fusiformes/diagnóstico , Nevo de Células Epitelioides y Fusiformes/patología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología
13.
Rev. bras. anal. clin ; 37(2): 117-118, 2005. ilus, tab
Artículo en Portugués | LILACS | ID: lil-509805

RESUMEN

No período de janeiro à dezembro de 2003 foram enviados ao Laboratório Central do estado do Ceará ( LACEN-Ce), 1.028 espécimes clínicos (urina), coletados de 112 pacientes com suspeita de tuberculose urogenital, onde 79 (7,7) destes espécimes apresentaram baciloscopia e cultura positiva para o complexo Mycobacterium tuberculosis. Dos 112 pacientes apenas 40 (35,7)...


Asunto(s)
Masculino , Femenino , Humanos , Tuberculosis Urogenital , Técnicas de Laboratorio Clínico , Mycobacterium tuberculosis
14.
Br J Dermatol ; 151(1): 157-64, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15270885

RESUMEN

BACKGROUND: Virtually all BCCs have deregulation of the Hedgehog (Hh) signalling pathway and a proportion show nuclear beta-catenin accumulation. The latter is thought to be due to Hh pathway-directed Wnt expression but this has not been tested. An alternative cause of nuclear beta-catenin accumulation is gene mutation, which stabilizes the protein. Theoretically, reduced E-cadherin expression could also be important because it can sequester beta-catenin at the cell membrane. In turn, nuclear beta-catenin can increase expression of MYC and cyclin D1, thus potentially altering proliferation. OBJECTIVES: To assess whether nuclear beta-catenin occurs in BCC, and to look at potential causes and consequences. METHODS: Nuclear beta-catenin was assessed by immunohistochemistry, and its causes by analysis of E-cadherin expression, beta-catenin exon 3 mutation and WNT5A expression. Its consequences were assessed by analysing proliferation. RESULTS: We found nuclear beta-catenin in 20 of 86 paraffin-embedded sections of BCCs using immunohistochemistry. BCCs showed increased WNT5A relative to the surrounding skin. No mutations in exon 3 of the beta-catenin gene were found in 10 cases. There was no association between beta-catenin localization and E-cadherin expression. Tumours with nuclear beta-catenin had significantly higher proliferation (P < 0.01). CONCLUSIONS: The absence of beta-catenin gene mutations indicate that the Hh pathway-directed Wnt signalling remains the most likely cause of nuclear beta-catenin accumulation in BCC. Additionally, the correlation with increased proliferation is the first evidence that nuclear beta-catenin may have a biological effect. However, a causal link between Hh pathway deregulation, Wnt ligand overexpression, nuclear beta-catenin accumulation and increased proliferation remains to be confirmed.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma Basocelular/química , Núcleo Celular/química , Proteínas del Citoesqueleto/análisis , Neoplasias Cutáneas/química , Transactivadores/análisis , Anciano , Cadherinas/análisis , Carcinoma Basocelular/genética , Carcinoma Basocelular/patología , División Celular , Distribución de Chi-Cuadrado , Ciclina D1/genética , Proteínas del Citoesqueleto/genética , Femenino , Expresión Génica , Genes myc , Humanos , Inmunohistoquímica/métodos , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas/análisis , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patología , Transactivadores/genética , Proteínas Wnt , Proteína Wnt-5a , beta Catenina
15.
Br J Dermatol ; 148(2): 195-202, 2003 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12588368

RESUMEN

The ideal classification of basal cell carcinoma (BCC) should be able to identify subtypes which correlate with clinical behaviour and treatment requirements. Unfortunately, however, such a classification has yet to be defined. In the interim, the currently most favoured classification is one based predominantly on histological growth pattern. This classification contributes to the useful concept of low- and high-risk histological subtypes of BCC. The latter are characterized by an increased probability of subclinical extension and/or incomplete excision and/or aggressive local invasive behaviour and/or local recurrence. The Royal College of Pathologists has published a minimum dataset for the histopathological reporting of BCC and this has been written to be compatible with the British Association of Dermatologists' management guidelines. Growth patterns to be reported include nodular, superficial, infiltrative/morphoeic and micronodular types, together with differentiation when of severely atypical or malignant squamous type (basosquamous carcinoma). Deep and peripheral excision margins will be reported to be either involved or clear. The latter will include a comment of a clearance of less than 1 mm for close margins and a measured distance in whole millimetres for other excisions. Clinical assessment and histology remain the 'gold standard' for evaluating BCC and cancers in general. However, in the postgenomic era emphasis is changing from the gathering and archiving of genomic data to its analysis and use in guiding clinical practice. In this context, a current goal is to define cancer phenotype in terms of molecular abnormalities and use this as a new gold standard. One way to assess whether this goal is being achieved for BCC is to determine whether our knowledge of its molecular pathology has any relevance to the minimum dataset for histological reporting. Knowledge of BCC molecular pathology has been fuelled by the recent discovery that deregulation of the Hedgehog (Hh) signalling pathway, a key player in embryonic patterning, appears to be fundamental to tumour growth. But despite accrual of a large amount of data concerning Hh pathway molecular alterations in neoplasia, little is known about the functional consequences of these changes in BCC, how they lead to tumour development, or how they relate to non-Hh pathway alterations such as TP53 mutation. Recent work suggests that the cellular localization of beta-catenin gives a degree of credence to the growth pattern classification of BCC. Furthermore, it is possible that beta-catenin may have a pathogenetic role in the invasive behaviour of BCC. This review draws on current evidence to discuss these issues and assess whether they are relevant to the minimum dataset.


Asunto(s)
Carcinoma Basocelular/genética , Neoplasias Cutáneas/genética , Carcinoma Basocelular/clasificación , Carcinoma Basocelular/patología , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/patología , Proteínas del Citoesqueleto/análisis , Regulación Neoplásica de la Expresión Génica/genética , Genes p53/genética , Proteínas Hedgehog , Humanos , Mutación/genética , Invasividad Neoplásica/patología , Recurrencia Local de Neoplasia/patología , Transducción de Señal/genética , Neoplasias Cutáneas/clasificación , Neoplasias Cutáneas/patología , Transactivadores/análisis , Transactivadores/genética , beta Catenina
16.
Br J Dermatol ; 147(5): 931-5, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12410703

RESUMEN

BACKGROUND: Superficial basal cell carcinoma (BCC) arises as an apparently multifocal proliferation of tumour nests attached to the epidermis, which is at odds with a monoclonal origin. Computer-assisted reconstruction shows that these nests join in three dimensions, but it remains unknown whether this tumour is monoclonal. An early event in BCC formation, loss of heterozygosity (LOH) at the Patched 1 (Ptch1) locus, can be used as a tool to address whether this tumour is monoclonal. OBJECTIVES: To determine whether superficial BCC is monoclonal by analysing individually microdissected superficial BCC nests and looking for the same pattern of LOH in each. METHODS: Six cases of superficial BCC were analysed for LOH at the Ptch1 gene locus using the D9S287 microsatellite marker. Identical allelic patterns were sought in each nest from a given tumour. These patterns were no allelic loss, loss of the shorter allele or loss of the longer allele, each with a respective probability of occurrence, as estimated from published findings. RESULTS: All cases were informative. Four cases showed no LOH in each nest and two showed loss of the same allele. If these nests arose independently, then the probability of this result was between 4 x 10-11 and 2 x 10-14. The lack of LOH, seen in four cases, could be due to monoclonal expansion of a cell retaining both D9S287 alleles, or due to a polyclonal proliferation. Therefore, a separate analysis excluding these cases was done, giving a probability of between 2.2 x 10-4 and 1.0 x 10-7. CONCLUSIONS: These probabilities were so extreme that it was unlikely that the nests arose independently, thus providing the first molecular evidence that superficial BCC is monoclonal.


Asunto(s)
Carcinoma Basocelular/patología , Proteínas de la Membrana/genética , Proteínas de Neoplasias/genética , Células Madre Neoplásicas/patología , Neoplasias Cutáneas/patología , Carcinoma Basocelular/genética , Cromosomas Humanos Par 9 , Humanos , Pérdida de Heterocigocidad , Repeticiones de Microsatélite , Receptores Patched , Receptor Patched-1 , Reacción en Cadena de la Polimerasa/métodos , Receptores de Superficie Celular , Neoplasias Cutáneas/genética
17.
J Pathol ; 193(4): 427-32, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11276000

RESUMEN

The Hedgehog signalling pathway is important in embryological development and is highly conserved through evolution. Recently Patched, a member of the pathway, was found to be important in Gorlin's syndrome. Inherited Patched gene mutations underlie the syndrome, in which a key feature is multiple basal cell carcinomas (BCCs). The gene is also mutated in sporadic BCCs as well as in sporadic occurrences of other tumours seen in Gorlin's syndrome. The precise mechanism whereby Patched gene mutation leads to tumour development is not known, but BCC is characterized by relentless local invasion and only rarely metastasizes. This suggests that abnormalities of the Hedgehog pathway account for these features. This proposal is discussed in the context of what is already known about the normal function of the Hedgehog pathway and its deregulation in cancer.


Asunto(s)
Carcinoma Basocelular/genética , Proteínas de Neoplasias/genética , Proteínas/genética , Transducción de Señal/genética , Transactivadores , Carcinoma Basocelular/patología , Proteínas Hedgehog , Humanos , Mutación , Invasividad Neoplásica
18.
J Neurol Neurosurg Psychiatry ; 69(4): 442-6, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-10990501

RESUMEN

OBJECTIVE: This study aimed to determine the usefulness of sural nerve biopsy in neurological practice. METHODS: The first prospective study of sural nerve biopsy in 50 consecutive patients was undertaken. The investigating neurologist declared the prebiopsy diagnosis and management plan and after 3 months an independent neurologist evaluated the contribution of the biopsy to diagnosis and management. An independent audit officer sought information from the patient about the adverse effects and value of the biopsy after 6 weeks and 6 months. RESULTS: In seven cases the nerve biopsy changed the diagnosis, in 35 cases the biopsy confirmed the suspected diagnosis, and in eight cases the biopsy was non-contributory. The biopsy either changed or was helpful in guiding patient management in 60%, especially those with demyelinating neuropathy and multiple mononeuropathy. Seven patients reported having had infection and 10 reported increased pain at the biopsy site 6 months later. CONCLUSION: In a consecutive series of 50 cases, sural nerve biopsy altered the diagnosis in 14%, affected management in 60%, and caused persistent increased pain at the biopsy site in 33%.


Asunto(s)
Biopsia , Enfermedades del Sistema Nervioso Periférico/patología , Nervio Sural/patología , Potenciales de Acción/fisiología , Adolescente , Adulto , Anciano , Biopsia/efectos adversos , Femenino , Humanos , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Estudios Prospectivos , Nervio Sural/fisiopatología , Nervio Sural/ultraestructura
20.
J Neurol Neurosurg Psychiatry ; 66(3): 390-2, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10084541

RESUMEN

The peptidergic sensory innervation of cranial blood vessels may play an important part in vascular head pain. The neuropeptides calcitonin gene-related peptide (CGRP) and substance P in sensory fibres are dependent on nerve growth factor (NGF) produced by the blood vessels, and when released from nerve terminals mediate neurogenic inflammation. NGF is increased in inflamed tissues, and acts via its high affinity receptor trk A on nociceptor fibres to produce hyperalgesia. CGRP and trk A immunoreactive nerve fibres have therefore been studied, for the first time, in inflamed (n=7) and non-inflamed (n=10) temporal arteries biopsied from patients with headache and suspected giant cell arteritis. CGRP immunoreactivity was markedly decreased to absent in adventitial nerve fibres in inflamed regions of vessels, which may reflect secretion from nerve terminals, as CGRP immunoreactivity could still be seen in nerve trunks in periadventitial tissue. Trk A immunoreactive nerve fibres were found in a similar distribution to CGRP containing nerve fibres in non-inflamed vessels, and the trk A immunoreactivity was virtually unchanged in inflamed vessels. The evidence supports a role for NGF related mechanisms in inflammatory vascular head pain. Anti-NGF or anti-trk A agents may represent novel analgesics in this condition.


Asunto(s)
Péptido Relacionado con Gen de Calcitonina/inmunología , Arteritis de Células Gigantes/inmunología , Proteínas Proto-Oncogénicas/inmunología , Proteínas Tirosina Quinasas Receptoras/inmunología , Receptores de Factor de Crecimiento Nervioso/inmunología , Arterias Temporales/inmunología , Adulto , Anciano , Humanos , Inmunohistoquímica , Inflamación/inmunología , Persona de Mediana Edad , Receptor trkA
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA